Novo Nordisk is a healthcare company that was founded in 1923 and headquartered outside Copenhagen, Denmark. The company's purpose is to drive change to tackle diabetes and many other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.
The company operates by pioneering scientific breakthroughs, expanding access to its medicines and working haard to prevent and cure the diseases it treats.
The company focuses on the serious chronic diseases that affect several millions of people, by addressing one of the most urgent global health challenges.
By combining its innovation and commercial excellence, the company draws upon insights from patients and partners to revolutionalize bold ideas into life-saving and preventive medicines.
The company makes long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to advance the development of digital health solutions and medical devices.
The treatments, produced by Novonordisk are:
Tresiba®, insulin degludec
Xultophy®*, insulin degludec/liraglutide
Levemir®, insulin detemir
Insulatard®, human insulin
Actrapid®, human insulin
Mixtard® 30, biphasic human insulin
Mixtard® 40, biphasic human insulin
Mixtard® 50, biphasic human insulin
Ryzodeg® 70/30, insulin degludec/insulin aspart
NovoMix® 30, biphasic insulin aspart
NovoMix® 50, biphasic insulin aspart
NovoMix® 70, biphasic insulin aspart
Glucagon-like peptide-1 (GLP-1)
Rybelsus, oral semaglutide
Fiasp®, insulin aspart
NovoRapid® **, insulin aspart
NovoRapid® PumpCart®, pre-filled insulin pump cartridge
Oral antidiabetic agents